These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 17598097)

  • 1. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.
    Watson J; Wise L; Green J
    Eur J Clin Pharmacol; 2007 Sep; 63(9):843-9. PubMed ID: 17598097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women.
    Velthuis-Te Wierik EJ; Hendricks PT; Martinez C
    Menopause; 2007; 14(3 Pt 1):518-27. PubMed ID: 17224856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations.
    Salagame U; Kliewer EV; Demers A; Banks E; Velentzis LS; Goldsbury D; Egger S; Leslie WD; Canfell K
    J Womens Health (Larchmt); 2020 Feb; 29(2):177-186. PubMed ID: 31895627
    [No Abstract]   [Full Text] [Related]  

  • 4. [Utilization of hormone replacement therapy in Spain: Trends in the period 2000-2014].
    Baladé Martínez L; Montero Corominas D; Macías Saint-Gerons D
    Med Clin (Barc); 2016 Oct; 147(7):287-92. PubMed ID: 27423654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
    Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
    Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study.
    Huot L; Couris CM; Tainturier V; Jaglal S; Colin C; Schott AM
    Osteoporos Int; 2008 Jul; 19(7):1047-54. PubMed ID: 18373055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
    Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
    Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tibolone: a unique version of hormone replacement therapy.
    Swegle JM; Kelly MW
    Ann Pharmacother; 2004 May; 38(5):874-81. PubMed ID: 15026563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.
    Cadarette SM; Carney G; Baek D; Gunraj N; Paterson JM; Dormuth CR
    Osteoporos Int; 2012 Apr; 23(4):1475-80. PubMed ID: 21901476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women's Health Initiative study.
    Kang BM; Kim MR; Park HM; Yoon BK; Lee BS; Chung HW; Cho SH; Choi H; Kim JG
    Menopause; 2006; 13(1):125-9. PubMed ID: 16607108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
    Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
    BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National use of postmenopausal hormone therapy: annual trends and response to recent evidence.
    Hersh AL; Stefanick ML; Stafford RS
    JAMA; 2004 Jan; 291(1):47-53. PubMed ID: 14709575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.
    Gold DT; Bonnick SL; Amonkar MM; Kamel HK; Agarwal S; Zaidi M
    Gend Med; 2008 Dec; 5(4):374-84. PubMed ID: 19108810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study.
    Wierik EJ; Hendricks PT; Boerstoel-Streefland M
    Climacteric; 2004 Jun; 7(2):197-209. PubMed ID: 15497909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study.
    Faber A; Bouvy ML; Loskamp L; van de Berg PB; Egberts TC; de Jong-van den Berg LT
    Br J Clin Pharmacol; 2005 Dec; 60(6):641-7. PubMed ID: 16305589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates.
    Foster SA; Foley KA; Meadows ES; Johnston JA; Wang S; Pohl GM; Long SR
    BMC Womens Health; 2008 Dec; 8():24. PubMed ID: 19105828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Legacy Drug-Prescribing Patterns in Primary Care.
    Mangin D; Lawson J; Cuppage J; Shaw E; Ivanyi K; Davis A; Risdon C
    Ann Fam Med; 2018 Nov; 16(6):515-520. PubMed ID: 30420366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy in the WHI era.
    Burger HG
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):84-91. PubMed ID: 16638027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menopause-related workload in general practice 1996-2005: a retrospective study in the UK.
    Iversen L; Delaney EK; Hannaford PC; Black C
    Fam Pract; 2010 Oct; 27(5):499-506. PubMed ID: 20530133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.